Updated ENZAMET Data Underscore Long-term OS Benefit With Enzalutamide in mHSPC
June 5th 2022The addition of enzalutamide vs a conventional nonsteroidal antiandrogen agent to testosterone suppression continued to provide clinically meaningful improvements in overall survival in patients with metastatic hormone-sensitive prostate cancer.
177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After Docetaxel
June 5th 2022177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities
Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer
June 4th 2022Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.
Single-Agent Cabozantinib Stalls as Maintenance Therapy in Advanced Urothelial Cancer
June 4th 2022Results of the ATLANTIS study do not support further investigation of cabozantinib alone as a maintenance therapy after platinum-based chemotherapy in unselected patients with advanced urothelial cancer.